ResearcherHacettepe UniversityActive in the last 2 years
Deniz Can Güven
Matched on ORCID iD 0000-0002-6924-9467; OpenAlex author ID A5101787110. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers
Papers 7
- Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy. Co-author DOI 10.1007/s10147-024-02512-4↗
- The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.01.009↗
- Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer. First author DOI 10.1016/j.clinre.2023.102091↗
- A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer. Co-author DOI 10.1097/cad.0000000000001486↗
- A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2021.103528↗
- The relation between inflammation-based parameters and survival in metastatic pancreatic cancer. Co-author DOI 10.4103/jcrt.jcrt_773_19↗
- All Positives May Not Be the Same in Pancreatic Cancer: Lessons Learned From the Past. First author DOI 10.1097/coc.0000000000000723↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Şuayib Yalçın · 6 shared papers, 2021–2024 · strength 1.14
- Paper The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic duc… DOI 10.1016/j.pan.2024.01.009↗
- Paper Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line che… DOI 10.1007/s10147-024-02512-4↗
- Paper A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant m… DOI 10.1097/cad.0000000000001486↗
- Ömer Dızdar · 6 shared papers, 2020–2024 · strength 1.12
- Paper The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic duc… DOI 10.1016/j.pan.2024.01.009↗
- Paper Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line che… DOI 10.1007/s10147-024-02512-4↗
- Paper A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant m… DOI 10.1097/cad.0000000000001486↗
- Taha Koray Şahin · 5 shared papers, 2020–2024 · strength 0.91
- Paper The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic duc… DOI 10.1016/j.pan.2024.01.009↗
- Paper Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line che… DOI 10.1007/s10147-024-02512-4↗
- Paper Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic ca… DOI 10.1016/j.clinre.2023.102091↗
- Furkan Ceylan · 4 shared papers, 2020–2024 · strength 0.75
- Paper The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic duc… DOI 10.1016/j.pan.2024.01.009↗
- Paper Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line che… DOI 10.1007/s10147-024-02512-4↗
- Paper Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic ca… DOI 10.1016/j.clinre.2023.102091↗
- Hasan Çağrı Yıldırım · 1 shared paper, 2023 · strength 0.20
- Sema Türker · 1 shared paper, 2021 · strength 0.17
- Saadettin Kılıçkap · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.